OCS Plummets 23% on Phase 3 Failure and Shareholder Probe

What happened

Oculis Holding AG's stock collapsed 23.4% after disclosing that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet primary endpoints in diabetic macular edema. A shareholder investigation has been launched, alleging the company claimed the drug was 'biologically approved' months earlier, raising potential securities law violations. The DeepValue master report had already flagged asymmetric downside risk, with a bear case of $12 if DIAMOND failed, and the news validates that scenario while adding legal risk. The crowded consensus of a de-risked platform is shattered, and the stock's probability-weighted value now skews heavily toward the bear case. Management credibility is severely damaged, likely complicating financing and partnership efforts.

Implication

The probability of the bear case ($12) has risen to >50% given legal and clinical risks. Any remaining holders should severely reduce positions and await clarity on cash runway and legal liability.

Thesis delta

The thesis has shifted from a binary Phase 3 readout with manageable downside to an active legal and regulatory crisis. The prior probability-weighted base case of $26 is no longer credible; the bear case of $12 has become the most likely outcome, with additional downside possible from litigation costs and management distraction. The company's credibility is damaged, making future partnership and financing more difficult.